Role of eicosanoids and white blood cells in the beneficial effects of limited reperfusion after ischemia-reperfusion injury in skeletal muscle.
Limiting the rate of reperfusion blood flow has been shown to be beneficial locally in models of ischemia-reperfusion injury. We investigated the effects of this on eicosanoids (thromboxane B2, 6-keto-PGF1 alpha, and leukotriene B4), white blood cell activation, and skeletal muscle injury as quantitated by triphenyltetrazolium chloride and technetium-99m pyrophosphate after ischemia-reperfusion injury in an isolated gracilis muscle model in 16 anesthetized dogs. One gracilis muscle in each dog was subjected to 6 hours of ischemia followed by 1 hour of limited reperfusion and then by a second hour of normal reperfusion. The other muscle was subjected to 6 hours of ischemia followed by 2 hours of normal reperfusion. Six dogs each were used as normal reperfusion controls (NR) and limited reperfusion controls (LR), with 5 dogs being treated with a thromboxane synthetase inhibitor (LR/TSI) and another five with a leukotriene inhibitor (LR/LI). LR in all three groups (LR, LR/TSI, and LR/LI) showed a benefit in skeletal muscle injury as measured by triphenyltetrazolim chloride and technetium-99m pyrophosphate when compared with NR. However, there was no significant difference between the groups with LR regarding eicosanoid levels and white blood cell activation when compared with NR. These results demonstrate that LR produces benefits by mechanisms other than those dependent upon thromboxane A2, prostacyclin, or white blood cell activation.
Anderson
R J
RJ
UMDNJ-New Jersey Medical School, Newark 07103-2757.
Cambria
R A
RA
Dikdan
G
G
Lysz
T W
TW
Hobson
R W
RW
D000818:Animals; D001783:Blood Flow Velocity; D011756:Diphosphates; D004195:Disease Models, Animal; D004285:Dogs; D015777:Eicosanoids / Q000097:blood*; D007962:Leukocytes / Q000502:physiology*; D009132:Muscles / Q000293:injuries* / Q000503:physiopathology; D015427:Reperfusion Injury / Q000097:blood / Q000503:physiopathology / Q000628:therapy*; D013667:Technetium; D016698:Technetium Tc 99m Pyrophosphate; D013778:Tetrazolium Salts; D013997:Time Factors
D011756:Diphosphates; D015777:Eicosanoids; D013778:Tetrazolium Salts; D016698:Technetium Tc 99m Pyrophosphate; D013667:Technetium; C009591:triphenyltetrazolium